Abstract
BackgroundIRF5 is one member of IRFs family, and is critical for host immunity and cell response. In the present study, we sought to search the clinical and prognostic value of IFR5 in patients with non-metastatic ccRCC.ResultsIRF5 proved to be an adverse independent prognostic factor for overall survival (p < 0.001) and recurrence free survival (p = 0.002). The newly built nomograms could give better prediction for overall survival and recurrence free survival in ccRCC patients.Materials and MethodsWe included 264 individuals who were diagnosed with non-metastatic clear cell renal cell carcinoma in the present study. Immunohistochemistry staining was performed on tissue microarrays to evaluate the IRF5 expression. χ2 test, Fisher's exact test, t test, Kaplan-Meier method and Cox proportional hazard model were applied to evaluate the prognostic value of IRF5. Two nomograms were constructed to predict clinical outcomes for ccRCC patients after surgery.ConclusionsIRF5 was an adverse independent prognostic factor for both overall survival and recurrence free survival in patients with non-metastatic ccRCC.
Highlights
Renal cell carcinoma (RCC) represents 3% of all malignant tumors in adults [1]
Immunohistochemistry staining was performed on tissue microarrays to evaluate the Interferon regulatory factory 5 (IRF5) expression. χ2 test, Fisher's exact test, t test, Kaplan-Meier method and Cox proportional hazard model were applied to evaluate the prognostic value of IRF5
According to IRF5 expression, 30.3% (80/264) of patients were defined as high IRF5 expression
Summary
Renal cell carcinoma (RCC) represents 3% of all malignant tumors in adults [1]. The majority of RCC (70%) are classified as clear cell renal cell carcinoma (ccRCC) [2]. Despite most newly diagnosed RCC cases are early-stage and organ confined, approximately 25–30% of patients with RCC are presented with metastatic RCC (mRCC) at the time of diagnosis [3, 4]. Meantime 30% of the patients with localized disease will develop metastases even after the curative surgeries [5]. IRF5 is one member of IRFs family, and is critical for host immunity and cell response. We sought to search the clinical and prognostic value of IFR5 in patients with non-metastatic ccRCC
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
